Clinical utility of different botulinum neurotoxin preparations

Steven B. Abrams, Mark Hallett

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for " botulinum neurotoxins" will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalToxicon
Volume67
DOIs
StatePublished - Jun 1 2013

Fingerprint

Urology
Neurotoxins
Literature
Movement Disorders
Expert Testimony
Publications
Patient Care
Clinical Trials
Physicians
Safety
Research
Therapeutics

Keywords

  • AbobotulinumtoxinA
  • Chemodenervation
  • Evidenced-based review
  • IncobotulinumtoxinA
  • OnabotulinumtoxinA
  • RimabotulinumtoxinB

ASJC Scopus subject areas

  • Toxicology

Cite this

Clinical utility of different botulinum neurotoxin preparations. / Abrams, Steven B.; Hallett, Mark.

In: Toxicon, Vol. 67, 01.06.2013, p. 81-86.

Research output: Contribution to journalArticle

@article{ab7b754918474fadb759345429d7133c,
title = "Clinical utility of different botulinum neurotoxin preparations",
abstract = "Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for {"} botulinum neurotoxins{"} will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.",
keywords = "AbobotulinumtoxinA, Chemodenervation, Evidenced-based review, IncobotulinumtoxinA, OnabotulinumtoxinA, RimabotulinumtoxinB",
author = "Abrams, {Steven B.} and Mark Hallett",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.toxicon.2012.11.024",
language = "English (US)",
volume = "67",
pages = "81--86",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Clinical utility of different botulinum neurotoxin preparations

AU - Abrams, Steven B.

AU - Hallett, Mark

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for " botulinum neurotoxins" will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.

AB - Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for " botulinum neurotoxins" will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.

KW - AbobotulinumtoxinA

KW - Chemodenervation

KW - Evidenced-based review

KW - IncobotulinumtoxinA

KW - OnabotulinumtoxinA

KW - RimabotulinumtoxinB

UR - http://www.scopus.com/inward/record.url?scp=84877709426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877709426&partnerID=8YFLogxK

U2 - 10.1016/j.toxicon.2012.11.024

DO - 10.1016/j.toxicon.2012.11.024

M3 - Article

C2 - 23375537

AN - SCOPUS:84877709426

VL - 67

SP - 81

EP - 86

JO - Toxicon

JF - Toxicon

SN - 0041-0101

ER -